Cytokinetics, Incorporated or PTC Therapeutics, Inc.: Who Leads in Yearly Revenue?

PTC Therapeutics leads in biotech revenue growth over a decade.

__timestampCytokinetics, IncorporatedPTC Therapeutics, Inc.
Wednesday, January 1, 20144694000022963000
Thursday, January 1, 20152865800036766000
Friday, January 1, 201610640700082705000
Sunday, January 1, 201713368000194392000
Monday, January 1, 201831501000264734000
Tuesday, January 1, 201926868000306980000
Wednesday, January 1, 202055828000380766000
Friday, January 1, 202170428000538593000
Saturday, January 1, 202294588000698801000
Sunday, January 1, 20237530000937822000
Loading chart...

Igniting the spark of knowledge

A Tale of Two Biotechs: Revenue Race from 2014 to 2023

In the competitive world of biotechnology, revenue growth is a key indicator of success. Over the past decade, Cytokinetics, Incorporated and PTC Therapeutics, Inc. have been vying for leadership in annual revenue. From 2014 to 2023, PTC Therapeutics has consistently outpaced Cytokinetics, with a staggering 900% increase in revenue, peaking at approximately $938 million in 2023. In contrast, Cytokinetics experienced a more modest growth, with revenue fluctuating and reaching its highest point in 2016 at around $106 million.

The data reveals a clear trend: PTC Therapeutics has maintained a steady upward trajectory, particularly from 2017 onwards, where it saw a significant surge, doubling its revenue by 2021. Meanwhile, Cytokinetics faced a decline in 2023, dropping to just $7.5 million. This analysis underscores the dynamic nature of the biotech industry and highlights PTC Therapeutics as a formidable leader in revenue growth.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025